[ad_1]
- The European Medicines Agency, the European Union’s drug regulator, recommended on Monday the authorization of the Pfizer and BioNTech COVID-19 vaccine.
- The decision paves the way for EU citizens to access a COVID-19 vaccine.
- Pfizer recently published data that suggested the vaccine was 95% effective in preventing COVID-19 cases in late-stage trials.
- Visit the Business Insider home page for more stories.
The European Union’s drug regulator recommended Monday that it authorize the Pfizer and BioNTech COVID-19 vaccine.
Experts from the Human Medicines Committee of the European Medicines Agency concluded that the Pfizer vaccine was safe and effective for people over 16 years of age. The decision paves the way for an EU-wide authorization of the vaccine.
On December 2, the UK became the first Western nation to approve the Pfizer vaccine. He began to inoculate citizens shortly after.
Read more: Amazon is quietly building a business to offer healthcare to major companies. Here’s an inside look at Amazon Care.
Pfizer published data that suggested the vaccine was 95% effective in preventing COVID-19 cases in late-stage trials.
“Today’s positive news is an important step forward in our fight against this pandemic, which has caused suffering and hardship for many,” Emer Cooke, EMA CEO, said in a statement.
Cooke said the agency will continue to collect and analyze data on the Pfizer vaccine.
This is a story in development.
